![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Accepted Manuscript)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
813kB |
Preview |
PDF (Supplementary Information)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
694kB |
| Item Type: | Article |
|---|---|
| Title: | Costs and health-related quality of life in patients with NMO spectrum disorders and MOG-antibody-associated disease: CHANCE(NMO) study |
| Creators Name: | Hümmert, M.W., Schöppe, L.M., Bellmann-Strobl, J., Siebert, N., Paul, F., Duchow, A., Pellkofer, H., Kümpfel, T., Havla, J., Jarius, S., Wildemann, B., Berthele, A., Bergh, F.T., Pawlitzki, M., Klotz, L., Kleiter, I., Stangel, M., Gingele, S., Weber, M.S., Faiss, J.H., Pul, R., Walter, A., Zettl, U., Senel, M., Stellmann, J.P., Häußler, V., Hellwig, K., Ayzenberg, I., Aktas, O., Ringelstein, M., Schreiber-Katz, O. and Trebst, C. |
| Abstract: | OBJECTIVE: To evaluate costs and health-related quality of life (HRQoL) of neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein-antibody associated disease (MOGAD).MethodsIn this multicenter cross-sectional study, data on consumption of medical and non-medical resources and work ability were assessed via patient questionnaires. Costs were analyzed in EUR for 2018 from the societal perspective. HRQoL was captured by the EuroQoL EQ-5D-5L questionnaire. Clinical data were retrieved from the Neuromyelitis Optica Study Group (NEMOS) database. RESULTS: Two hundred twelve patients (80% women; median age 50 [19-83] years; median disease duration 7 [0-43] years; median Expanded Disability Status Scale [EDSS] 3.5 [0-8.5]; 66% Aquaporin-4 IgG, 22% MOG IgG positive, 12% double seronegative) were analyzed. The mean total annual per capita cost of illness accounted for EUR (Euro) 59 574 (95% CI 51 225 to 68 293; USD [United States dollars] 70 297, 95% CI 60 445 to 80 586), and the mean index value of the EQ-5D-5L was 0.693 (95% CI 0.65 to 0.73). The most important cost drivers were informal care costs (28% of total costs), indirect costs (23%) and drugs (16%), especially immunotherapeutics. Costs showed a positive correlation with disease severity (ρ=0.56, 95% CI 0.45 to 0.65); in the EDSS 6.5-8.5 subgroup the mean annual costs were EUR 129 687 (95% CI 101 946 to 160 336; USD 153 031, 95% CI 120 296 to 189 196). The HRQoL revealed a negative correlation to disease severity (ρ=-0.69, 95% CI -0.76 to -0.61); in the EDSS 6.5-8.5 subgroup the EQ-5D-5L mean index value was 0.195 (95% CI 0.13 to 0.28). Neither antibody status nor disease duration influenced the total annual costs or HRQoL. CONCLUSION: These German data from the era without approved preventive immunotherapies show enormous effects of the diseases on costs and quality of life. An early and cost-effective therapy should be provided to prevent long-term disability and preserve quality of life. |
| Keywords: | Aquaporin 4, Autoantibodies, Cross-Sectional Studies, Myelin-Oligodendrocyte Glycoprotein, Neuromyelitis Optica, Quality of Life |
| Source: | Neurology |
| ISSN: | 0028-3878 |
| Publisher: | American Academy of Neurology |
| Volume: | 98 |
| Number: | 11 |
| Page Range: | e1184-e1196 |
| Date: | 15 March 2022 |
| Official Publication: | https://doi.org/10.1212/WNL.0000000000200052 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
